GLP-2 / Teduglutide (Gattex): The Complete Guide

Overview

Glucagon-like peptide-2 (GLP-2) is a 33-amino acid peptide hormone produced by enteroendocrine L-cells in the distal small intestine and colon. It is derived from the same proglucagon precursor protein that yields GLP-1 — the hormone behind blockbuster diabetes and obesity medications like semaglutide and tirzepatide. GLP-2 and GLP-1 are co-secreted in response to nutrient ingestion, but they serve profoundly different physiological roles: while GLP-1 regulates glucose metabolism and appetite, GLP-2 is a dedicated intestinotrophic factor — its primary job is to maintain and repair the intestinal lining (Drucker et al., 1996).

The intestinotrophic properties of GLP-2 were discovered in 1996 by Daniel Drucker's laboratory, when they demonstrated that GLP-2 administration dramatically increased small intestinal weight, villus height, and crypt depth in mice. This discovery opened a new therapeutic avenue: if GLP-2 could stimulate intestinal growth, it might help patients who had lost large portions of their intestine to surgery or disease (Drucker et al., 1996).

Native GLP-2 has a very short plasma half-life of approximately 7 minutes, because it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) — the same enzyme that degrades GLP-1. To create a therapeutically viable drug, researchers introduced a single amino acid substitution at position 2 (glycine to alanine), rendering the molecule resistant to DPP-4 degradation. This analog — teduglutide — has a half-life of approximately 2 hours, making once-daily subcutaneous injection feasible (Drucker, 2005).

Teduglutide was developed by NPS Pharmaceuticals under the brand name Gattex (known as Revestive outside the United States). It received FDA approval in December 2012 for the treatment of adults with short bowel syndrome (SBS) who are dependent on parenteral support (intravenous nutrition). In 2019, approval was extended to pediatric patients aged 1 year and older. Gattex is now marketed by Takeda Pharmaceutical Company.

For GLPbase readers: Understanding GLP-2 is essential context for anyone following GLP-1 science. These peptides are literal siblings — born from the same gene, released from the same cells, degraded by the same enzyme. The GLP-1 story is about glucose and appetite. The GLP-2 story is about gut integrity. Together, they represent the two arms of the L-cell response to food.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

The Proglucagon Connection: GLP-1 and GLP-2 as Sister Peptides

To understand GLP-2, you must first understand its origin. Both GLP-1 and GLP-2 are derived from the proglucagon gene (GCG). In the pancreatic alpha cells, proglucagon is processed by prohormone convertase 2 (PC2) to yield glucagon. In the intestinal L-cells and certain brain neurons, proglucagon is processed by prohormone convertase 1/3 (PC1/3) to yield a different set of peptides: GLP-1, GLP-2, oxyntomodulin, and glicentin (Drucker, 2005).

This means that every time an L-cell secretes GLP-1, it simultaneously secretes GLP-2 in approximately equimolar amounts. The two peptides are released together in response to nutrient ingestion, particularly carbohydrates and fats. They are also both degraded by the same enzyme — DPP-4 — which cleaves the first two amino acids from each peptide and inactivates them within minutes.

GLP-2 Receptor Signaling

GLP-2 acts through its specific receptor, the GLP-2 receptor (GLP-2R), a G-protein-coupled receptor (GPCR) of the secretin/glucagon family. Critically, the GLP-2R is not expressed on intestinal epithelial cells themselves. Instead, it is expressed on:

• Intestinal subepithelial myofibroblasts (ISEMFs): Mesenchymal cells located just beneath the epithelium. These cells receive the GLP-2 signal and release paracrine growth factors (including IGF-1, KGF/FGF-7, and EGF) that act on the neighboring epithelial cells to stimulate proliferation.
• Enteric neurons: GLP-2R is expressed in the enteric nervous system (submucosal and myenteric plexuses), mediating effects on blood flow, motility, and intestinal secretion.
• Enteroendocrine cells: Some evidence suggests GLP-2R expression on certain enteroendocrine cell populations.

This indirect signaling mechanism — GLP-2 acts on stromal cells, which then signal to epithelial cells — is a key distinction from many other growth factors and explains why GLP-2's trophic effects are specifically targeted to the intestinal mucosa (Brubaker, 2018).

Downstream Effects of GLP-2 Receptor Activation

When teduglutide binds GLP-2R, the following downstream effects are triggered:

• Intestinal epithelial proliferation: Increased crypt cell division rate, leading to expansion of the epithelial cell population. This is the primary intestinotrophic effect.
• Increased villus height: Taller villi mean greater absorptive surface area — directly improving nutrient absorption capacity.
• Increased crypt depth: Deeper crypts reflect enhanced stem cell activity and epithelial renewal.
• Reduced apoptosis: GLP-2 decreases programmed cell death in intestinal epithelial cells, shifting the balance toward net tissue growth.
• Enhanced barrier function: GLP-2 upregulates tight junction proteins (claudins, occludin, ZO-1), reducing intestinal permeability ("leaky gut").
• Reduced mucosal inflammation: GLP-2 has anti-inflammatory properties in the intestinal mucosa, reducing pro-inflammatory cytokine expression.
• Increased mesenteric blood flow: GLP-2R activation on enteric neurons promotes splanchnic vasodilation, improving blood supply to the gut.
• Reduced gastric acid secretion and gastric emptying: Slowing of gastric transit, which may improve nutrient contact time with absorptive epithelium.

GLP-1 vs. GLP-2: The Two Arms of the L-Cell Response

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Discovery: The Intestinotrophic Factor (1996)

The pivotal discovery came from Daniel Drucker's laboratory at the University of Toronto. While studying proglucagon-derived peptides, the group demonstrated that GLP-2 administration in mice produced striking intestinal growth: a 50% increase in small bowel weight, significantly taller villi, and deeper crypts — with no effect on other organs. This was the first identification of GLP-2 as a specific intestinal growth factor, and it immediately suggested therapeutic potential for intestinal failure (Drucker et al., 1996).

Early Human Studies in Short Bowel Syndrome

Palle Jeppesen and colleagues at Rigshospitalet Copenhagen conducted the first human studies of GLP-2 in short bowel syndrome patients. Native GLP-2, administered subcutaneously three times daily for 35 days, produced significant improvements in intestinal wet weight absorption, energy absorption, and body weight in SBS patients. These studies provided proof-of-concept that GLP-2's intestinotrophic effects observed in animal models translated to meaningful clinical benefit in humans (Jeppesen et al., 2001).

The STEPS Clinical Trial Program

The definitive clinical evidence for teduglutide came from the STEPS (Studies of Teduglutide Effectiveness in Parenteral Nutrition-dependent Short Bowel Syndrome) program:

• STEPS-1 (Phase 3): A 24-week, randomized, double-blind, placebo-controlled trial in 83 adult SBS patients dependent on parenteral nutrition (PN). Teduglutide 0.05 mg/kg/day significantly reduced PN volume compared to placebo. At week 24, 63% of teduglutide-treated patients achieved at least a 20% reduction in PN volume, compared to 30% of placebo patients (p=0.002). The response was clinically meaningful, with some patients able to reduce PN by several days per week (Jeppesen et al., 2012).
• STEPS-2: An open-label extension study demonstrating that PN volume reductions achieved with teduglutide were maintained over 2 years, with some patients achieving further reductions with continued treatment. The study also demonstrated sustained safety over longer treatment durations (Jeppesen et al., 2011).
• STEPS-3 / Long-term extensions: Continued long-term follow-up data (up to 30+ months) confirmed durability of PN reduction and identified a subset of patients (approximately 10-15%) who were able to achieve complete weaning from PN — a transformative outcome for patients previously dependent on daily intravenous nutrition (Carter et al., 2020).

Teduglutide vs. Native GLP-2

Emerging Research Areas

• Inflammatory bowel disease (IBD): Preclinical studies have demonstrated that GLP-2 reduces mucosal inflammation and promotes mucosal healing in models of colitis. The anti-inflammatory and trophic properties of GLP-2 make it a logical candidate for Crohn's disease and ulcerative colitis, though no pivotal trials have been completed for these indications (Wallis et al., 2007).
• Chemotherapy-induced mucositis: Chemotherapy damages rapidly dividing intestinal epithelial cells, causing painful mucositis. GLP-2's ability to promote epithelial repair and reduce apoptosis has shown promise in preclinical models of chemotherapy-induced intestinal damage.
• Necrotizing enterocolitis (NEC): GLP-2 has shown protective effects in neonatal animal models of NEC, a devastating condition in premature infants. Research is ongoing but has not reached clinical trials.
• Intestinal permeability / "leaky gut": GLP-2's ability to upregulate tight junction proteins and strengthen the epithelial barrier has generated interest in its potential role in conditions associated with increased intestinal permeability. This remains largely experimental.
• Next-generation GLP-2R agonists: Several pharmaceutical companies are developing longer-acting GLP-2 receptor agonists (e.g., apraglutide/glepaglutide) with weekly or less frequent dosing, which could significantly improve patient convenience and compliance (Sigalet, 2018).

Limitations of the Research

• Small trial populations: SBS is a rare disease, so clinical trial populations are inherently small. The pivotal STEPS-1 trial enrolled only 83 patients.
• Neoplasia concern: Because GLP-2 promotes cell proliferation, there is a theoretical concern that long-term use could promote intestinal neoplasia. Colonoscopy surveillance is required, and long-term cancer safety data continues to accumulate.
• IBD data is preclinical: Despite compelling animal data, GLP-2 analogs have not yet proven efficacy in IBD clinical trials.
• Compounded GLP-2 is unstudied: Off-label use of compounded GLP-2 analogs for conditions like IBS or "leaky gut" has no clinical trial support.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indication: Short Bowel Syndrome (SBS)

Teduglutide is FDA-approved for the treatment of adults and pediatric patients (age 1 year and older) with short bowel syndrome who are dependent on parenteral support.

Short bowel syndrome occurs when a large portion of the small intestine is surgically removed or congenitally absent, leaving insufficient absorptive surface to maintain nutrition through oral intake alone. Common causes include:

• Crohn's disease: Repeated surgical resections for complications (strictures, fistulae, abscesses)
• Mesenteric ischemia: Loss of blood supply to the intestine requiring emergency resection
• Surgical complications: Adhesions, volvulus, or other conditions requiring bowel resection
• Trauma: Abdominal injuries requiring intestinal resection
• Congenital: Gastroschisis, intestinal atresia, or other congenital anomalies (pediatric)

SBS patients typically depend on parenteral nutrition (PN) — intravenous delivery of nutrients directly into the bloodstream — to survive. PN is life-saving but carries significant complications: central line infections (potentially fatal), liver disease, metabolic derangements, and profound impact on quality of life. Reducing or eliminating PN dependence is the primary therapeutic goal.

How Teduglutide Helps SBS Patients

Off-Label and Investigational Uses

Compounding Pharmacy Interest

There is growing interest in the functional and integrative medicine community in using GLP-2 analogs obtained through compounding pharmacies for "gut healing" applications — including IBS, intestinal permeability, post-antibiotic recovery, and general gut restoration. It is important to note that:

• Compounded GLP-2 analogs have not been evaluated in clinical trials for these indications
• Quality, purity, and potency of compounded products may vary significantly
• The safety profile established for Gattex in SBS patients may not directly apply to other populations
• The neoplasia concern (GLP-2 promotes cell proliferation) remains relevant regardless of the indication

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

FDA-Approved Dosing (Gattex Prescribing Information)

Source: Jeppesen et al. (2012) — STEPS trial, Gastroenterology; Drucker (2005) — GLP-2 pharmacology, JCEM.

Before Starting Treatment

The following assessments are required before initiating teduglutide:

• Colonoscopy with removal of polyps: Required within 6 months before starting treatment. GLP-2 promotes intestinal cell proliferation, and any existing polyps must be addressed before exposing the intestine to growth-promoting therapy.
• Baseline assessment of parenteral nutrition requirements: Volume, frequency, and composition of current PN regimen must be documented to track response.
• Small bowel imaging: Evaluation of remaining intestinal anatomy to guide treatment expectations.
• Renal function assessment: For dose adjustment in renal impairment.

Parenteral Nutrition Adjustment Protocol

Teduglutide does not replace parenteral nutrition immediately. Instead, PN volumes are gradually reduced as the intestine adapts:

• Weeks 1-4: Maintain current PN regimen while teduglutide takes effect. Monitor urine output and fluid status closely.
• Weeks 4+: Begin PN volume reduction in 10-20% increments based on: increased urine output (sign of improved fluid absorption), stable electrolytes, adequate oral/enteral intake, and clinical assessment.
• Ongoing: Continue gradual PN reduction based on clinical response. Some patients may reduce PN by 1-3 days per week; a small subset may achieve complete PN weaning.

Monitoring During Treatment

• Colonoscopy: At 1 year after initiation, then every 5 years (or sooner if clinically indicated). Mandatory surveillance for colorectal polyps and neoplasia.
• Fluid and electrolyte balance: Particularly sodium, potassium, and magnesium. Improved intestinal absorption may necessitate PN composition changes.
• Urine output: The most practical early indicator of improved intestinal absorption. Increasing urine output suggests more fluid is being absorbed enterally.
• Body weight: Monitor for fluid overload, particularly in the early weeks.
• Hepatic function: Gallbladder and biliary complications should be monitored.
• Stoma output: In patients with ostomies, decreased stoma output indicates improved absorption.

Reconstitution and Storage

• Supplied as: Lyophilized powder in single-use vials (3.8 mg per vial)
• Reconstitution: Reconstitute with 0.5 mL of provided diluent (sterile water for injection with preservative)
• After reconstitution: Administer within 3 hours if stored at room temperature, or refrigerate and use within 24 hours
• Unreconstituted storage: Refrigerate at 2-8 degrees C (36-46 degrees F). Do not freeze. Protect from light.

Compounded GLP-2 Analogs: A Note

Compounded GLP-2 analogs available through some pharmacies may have different concentrations, reconstitution requirements, and stability profiles. There is no standardized compounding protocol, and potency may vary between preparations. Patients using compounded products should work closely with their prescribing provider and pharmacist.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Clinical Trials Show

STEPS-1 Pivotal Trial Results (24 Weeks)

Source: Jeppesen et al., 2012, Gastroenterology

Long-Term Extension Results

What These Results Mean for Patients

To appreciate the significance of these numbers, consider what daily life looks like for an SBS patient on parenteral nutrition:

• Before teduglutide: A typical SBS patient may be connected to an IV pump for 10-16 hours per day, 5-7 days per week. The central venous catheter carries risk of life-threatening bloodstream infections (approximately 1 infection per 1,000 catheter-days). PN costs $100,000-$300,000 per year. Quality of life is severely impacted — travel, work, and daily activities are constrained by infusion schedules.
• Reducing PN by 1-2 days/week: This represents additional "free" days without IV infusion — dramatically improving quality of life, travel ability, and infection risk. Even modest PN reductions are clinically meaningful.
• Complete PN weaning (10-15% of patients): For the subset who achieve this, it is effectively a cure of their PN dependence — removing the central line, eliminating infection risk, and restoring near-normal daily life.

Predictors of Response

• Remaining bowel anatomy: Patients with intact colon in continuity tend to respond better (the colon contributes to fluid and electrolyte absorption).
• Baseline PN volume: Patients with moderate PN dependence may have better response rates than those requiring very high volumes.
• Underlying disease: Response does not appear to differ significantly by the underlying cause of SBS.
• Duration of treatment: Some patients who do not respond at 24 weeks show late responses with continued treatment, suggesting ongoing intestinal adaptation.

Off-Label Use Results: Limited Data

For off-label applications (IBD, gut barrier repair, functional GI conditions), no controlled clinical trial data exists. Anecdotal reports from functional medicine providers describe improvements in intestinal permeability markers and GI symptoms, but these observations are subject to all the standard caveats of uncontrolled clinical experience: placebo effect, concurrent interventions, selection bias, and publication bias.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Common Side Effects (from Clinical Trials)

Data from STEPS-1 pivotal trial. Jeppesen et al., 2012

Serious Safety Concerns

Fluid Management Complications

One of the most important practical safety issues is fluid overload. When teduglutide improves intestinal absorption, patients begin absorbing more fluid from oral and enteral sources. If parenteral nutrition volume is not concurrently reduced, the result is excess fluid — potentially causing edema, congestive symptoms, or electrolyte imbalances. Close monitoring of fluid status and proactive PN adjustment is essential.

Contraindications

• Active gastrointestinal malignancy — GLP-2 promotes cell proliferation and could accelerate tumor growth
• Known hypersensitivity to teduglutide or any excipient
• Active or suspected intestinal obstruction

Pediatric Safety

In pediatric patients (age 1+), the safety profile is generally consistent with that observed in adults. Additional monitoring for growth and development is recommended, as the long-term effects of chronic intestinal growth factor stimulation during childhood development are not fully characterized.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Approval History

International Regulatory Status

• European Union: Approved by EMA as Revestive (teduglutide) for SBS in adults and children. Similar indication and labeling to US approval.
• Canada: Approved for SBS.
• Japan: Approved by PMDA for SBS.
• Other markets: Available in multiple countries through Takeda's distribution network.

Orphan Drug Status and Market Exclusivity

Teduglutide holds orphan drug designation in both the US and EU. Short bowel syndrome meets the criteria for orphan designation because it affects fewer than 200,000 people in the United States (estimated prevalence: 10,000-20,000 patients requiring PN). Orphan drug status provides:

• 7 years of market exclusivity in the US (from FDA approval date)
• 10 years of market exclusivity in the EU
• Tax credits for clinical trial costs
• Reduced regulatory fees
• These protections have contributed to the very high pricing of Gattex

Compounded GLP-2 Analogs: Regulatory Considerations

Unlike many peptides in the compounding space (such as ipamorelin or BPC-157), teduglutide is an FDA-approved drug. This creates a different regulatory dynamic for compounding:

• 503A compounding pharmacies: May compound a copy of an approved drug if they can demonstrate a medical need for the compounded version (e.g., different formulation, different dose). This is more restricted than compounding of unapproved bulk substances.
• 503B outsourcing facilities: Similar restrictions apply. Compounding a copy of an approved drug requires demonstrating a shortage or other specific circumstances.
• Research chemical suppliers: GLP-2 peptides sold as "research chemicals" are not regulated as drugs and are not intended for human use.

REMS and Safety Monitoring

Gattex does not have a formal REMS (Risk Evaluation and Mitigation Strategy), but the prescribing information includes strong recommendations for colonoscopy surveillance and neoplasia screening. Takeda maintains a patient support program (Gattex OnePath) that includes patient education, injection training, and access assistance.

Pipeline: Next-Generation GLP-2R Agonists

Several next-generation GLP-2 receptor agonists are in clinical development, which could eventually provide additional treatment options:

• Apraglutide (VectivBio/Ironwood): A long-acting GLP-2 analog designed for once-weekly subcutaneous injection. Currently in Phase 3 clinical trials for SBS.
• Glepaglutide (Zealand Pharma): Another long-acting GLP-2 analog in clinical development. Phase 3 data expected.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Gattex (Teduglutide) Pricing

Why Is It So Expensive?

• Orphan drug pricing: SBS affects approximately 10,000-20,000 PN-dependent patients in the US. The development costs must be recovered across a tiny patient population, resulting in high per-patient pricing.
• Market exclusivity: Orphan drug protections limit generic/biosimilar competition.
• Complex manufacturing: Peptide drugs require specialized manufacturing facilities and quality control processes.
• Clinical development costs: Even small rare-disease trials are expensive to conduct.
• Cost offset argument: Manufacturers argue that teduglutide reduces PN costs ($100,000-$300,000/year), hospitalization for PN complications, and line infection treatment costs, partially offsetting the drug cost.

Insurance Coverage

For the approved SBS indication, insurance coverage is possible but requires significant documentation:

• Specialty pharmacy tier: Gattex is distributed through specialty pharmacies. Most commercial insurance plans and Medicare Part D cover it under specialty drug benefit with extensive prior authorization.
• Prior authorization requirements: Diagnosis of SBS, documentation of PN dependence, colonoscopy completion, specialist prescriber, and often a trial period with response assessment.
• Step therapy: Some payers may require documentation that conservative intestinal rehabilitation measures have been attempted.
• Patient assistance: Takeda's OnePath program provides copay assistance, free drug for eligible uninsured patients, and insurance navigation support.

Compounded GLP-2: Alternative Pricing

Cost Comparison: Gattex vs. Parenteral Nutrition

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Q: If I'm taking a GLP-1 drug like semaglutide, does that also give me GLP-2 benefits?

Answer: No. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) act exclusively on the GLP-1 receptor. They do not activate the GLP-2 receptor. While your body naturally co-secretes GLP-1 and GLP-2 together, pharmaceutical GLP-1 drugs are synthetic analogs that only mimic GLP-1 activity. To get GLP-2 receptor activation, you would need a separate GLP-2 analog like teduglutide. Interestingly, DPP-4 inhibitors (sitagliptin, etc.) do increase both endogenous GLP-1 and GLP-2 levels by blocking their shared degradation enzyme — though the GLP-2 increase from DPP-4 inhibitors has not been shown to be clinically significant for intestinal trophic effects (Drucker, 2005).

Q: Could GLP-2 cause cancer? Why is colonoscopy required?

Answer: GLP-2's primary mechanism — promoting intestinal cell proliferation — is both its therapeutic benefit and its theoretical risk. Any agent that stimulates cell division has the potential to promote the growth of pre-existing neoplastic cells. In clinical trials, some teduglutide-treated patients developed colorectal polyps. Whether GLP-2 causes de novo cancer formation or merely accelerates growth of existing precancerous lesions is not definitively established. The colonoscopy requirement is a prudent surveillance measure: remove any existing polyps before starting treatment, then monitor regularly. In long-term studies, the overall cancer incidence in teduglutide-treated patients has not been significantly elevated, but vigilance is appropriate given the mechanism (Carter et al., 2020).

Q: Is GLP-2 the same as "leaky gut treatment"?

Answer: GLP-2 does have demonstrated effects on intestinal permeability — it upregulates tight junction proteins (claudins, occludin, ZO-1) and strengthens the epithelial barrier in preclinical models. This has generated significant interest in the functional medicine community for conditions associated with increased intestinal permeability. However, "leaky gut" as a clinical entity is not well-defined in mainstream gastroenterology, and GLP-2 analogs have not been studied in clinical trials for this purpose. The FDA-approved use is strictly for SBS. Using GLP-2 analogs for intestinal permeability conditions is experimental, off-label, and carries the same safety considerations (including neoplasia surveillance) as the approved indication (Brubaker, 2018).

Q: Why is Gattex so expensive if it's just a small peptide?

Answer: The price reflects orphan drug economics rather than manufacturing complexity. SBS requiring PN affects only 10,000-20,000 patients in the US. The hundreds of millions of dollars spent on clinical development, regulatory approval, and ongoing pharmacovigilance must be spread across this tiny patient base. Additionally, orphan drug market exclusivity limits competition. The manufacturer argues that Gattex's cost is partially offset by PN cost reductions and avoided hospitalizations for catheter-related infections. This is a common dynamic in rare disease drug pricing, not unique to teduglutide.

Q: Can GLP-2 help with Crohn's disease or ulcerative colitis?

Answer: This is an area of active research interest. GLP-2 has both trophic (growth-promoting) and anti-inflammatory effects on the intestinal mucosa, and preclinical data in colitis models is encouraging. Small studies in Crohn's patients have shown improvements in disease activity indices. However, no Phase 3 clinical trial has demonstrated efficacy in IBD, and GLP-2 analogs are not approved for this indication. The theoretical concern about neoplasia is particularly relevant in IBD patients, who already have an elevated baseline risk of colorectal cancer. If GLP-2 analogs are eventually developed for IBD, the cancer surveillance component will be a critical part of the treatment protocol (Wallis et al., 2007).

Q: Are compounded GLP-2 analogs safe?

Answer: Compounded GLP-2 analogs from compounding pharmacies have not undergone the rigorous testing required for FDA-approved drugs. The purity, potency, sterility, and stability of compounded peptides can vary significantly between pharmacies. The clinical trial safety data for teduglutide applies specifically to the Gattex formulation — not to compounded versions. If you are considering a compounded GLP-2 product, it is important to work with a reputable 503A or 503B pharmacy, obtain certificates of analysis, and maintain the same colonoscopy surveillance recommended for the approved product. The neoplasia risk is inherent to the mechanism of action, regardless of the source of the peptide.

Q: What happens when you stop taking teduglutide?

Answer: When teduglutide is discontinued, the intestinal trophic effects gradually reverse. Villus height and crypt depth return toward their pre-treatment baseline over weeks to months. Patients who reduced their PN volumes during treatment typically require PN re-escalation after discontinuation. This means that teduglutide is generally considered a chronic (ongoing) therapy — the benefits are maintained only with continued treatment. This is an important consideration in treatment planning and cost analysis (Sigalet, 2018).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• GLP-2 is the "sister peptide" of GLP-1. Both are produced from the same proglucagon gene, co-secreted by the same intestinal L-cells, and degraded by the same enzyme (DPP-4). While GLP-1 regulates glucose and appetite, GLP-2 is a dedicated intestinal growth and repair factor. Understanding GLP-2 provides essential context for anyone following GLP-1 science.
• Teduglutide (Gattex) is an FDA-approved GLP-2 analog for short bowel syndrome. A single amino acid substitution (Gly→Ala at position 2) renders it resistant to DPP-4 degradation, extending its half-life from ~7 minutes to ~2 hours.
• The clinical evidence for SBS is robust. The STEPS pivotal trial showed that 63% of patients achieved at least a 20% reduction in parenteral nutrition volume at 24 weeks. Long-term data shows sustained benefits, with 10-15% of patients achieving complete PN independence — a transformative outcome.
• The mechanism involves indirect intestinal trophism: GLP-2 binds receptors on subepithelial myofibroblasts and enteric neurons (not directly on epithelial cells), triggering paracrine release of growth factors that promote villus growth, crypt proliferation, barrier repair, and reduced inflammation.
• Colonoscopy surveillance is mandatory. Because GLP-2 promotes intestinal cell proliferation, there is a theoretical concern about accelerating neoplastic growth. Colonoscopy before and during treatment is required.
• Gattex is extremely expensive at over $300,000/year, reflecting orphan drug pricing for a rare disease. Compounded GLP-2 analogs are available at lower cost but without the same quality assurance or clinical trial support.
• Research interest extends beyond SBS: IBD, chemotherapy-induced mucositis, NEC, and intestinal permeability are all areas of active investigation, but none have reached Phase 3 clinical trials.
• Off-label use for "gut healing" is experimental and not supported by clinical trial data. The same safety considerations (including neoplasia risk) apply regardless of the indication.
• Next-generation GLP-2R agonists (apraglutide, glepaglutide) with weekly dosing are in late-stage clinical development and may expand access and convenience.

Questions to Ask a Provider

• Is my intestinal condition one where GLP-2 therapy has established evidence (SBS) or is it an off-label application?
• Have I completed the required colonoscopy screening before starting any GLP-2 analog?
• What is my specific treatment goal — PN reduction, PN weaning, or gut barrier improvement?
• Am I a candidate for the FDA-approved product (Gattex) with insurance coverage, or would a compounded formulation be the access route?
• What monitoring schedule (colonoscopy, labs, fluid assessment) will be followed?
• What is the realistic timeline for response, and what criteria will be used to assess whether treatment is working?
• If I stop treatment, what should I expect in terms of reversal of effects?
• Are there next-generation GLP-2R agonists in clinical trials that I might be eligible for?
• If using a compounded product, what quality testing and certificates of analysis are available?
• How does this fit into my overall GI management plan?

Sources & Further Reading

Discovery & Foundational Research

• Drucker DJ, Erlich P, Asa SL, Bhatt RS (1996) — "Induction of intestinal epithelial proliferation by glucagon-like peptide 2" — Proceedings of the National Academy of Sciences (PNAS)
• Drucker DJ (2005) — "Biologic actions and therapeutic potential of the proglucagon-derived peptides" — Journal of Clinical Endocrinology & Metabolism
• Brubaker PL (2018) — "Glucagon-like peptide-2 and the regulation of intestinal growth and function" — Comprehensive Physiology

Early Clinical Studies

• Jeppesen PB, Hartmann B, Thulesen J, et al. (2001) — "Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon" — Gastroenterology
• Wallis K, Walters JR, Gabe SM (2007) — "Short bowel syndrome: the role of GLP-2 in improving outcome" — Current Opinion in Clinical Nutrition and Metabolic Care

Pivotal Clinical Trials (STEPS Program)

• Jeppesen PB, Gilroy R, Pertkiewicz M, et al. (2011) — "Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome" — Gut
• Jeppesen PB, Pertkiewicz M, Messing B, et al. (2012) — "Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure" — Gastroenterology

Long-Term Safety & Efficacy

• Carter BA, Cohran VC, Cole CR, et al. (2020) — "Outcomes from a 12-month, open-label study of teduglutide in pediatric short bowel syndrome" — Journal of Pediatric Gastroenterology and Nutrition

GLP-2 Biology & Receptor Pharmacology

• Drucker DJ (2005) — "Biologic actions and therapeutic potential of the proglucagon-derived peptides" — JCEM
• Brubaker PL (2018) — "Glucagon-like peptide-2 and the regulation of intestinal growth and function" — Comprehensive Physiology

Therapeutic Reviews & Pipeline

• Sigalet DL (2018) — "New insight on the role of GLP-2 in the treatment of short bowel syndrome" — Current Opinion in Clinical Nutrition and Metabolic Care
• Wallis K, Walters JR, Gabe SM (2007) — "Short bowel syndrome: the role of GLP-2 in improving outcome"

Intestinal Adaptation & Emerging Indications

• Drucker DJ et al. (1996) — Original discovery of GLP-2 intestinotrophic properties — PNAS
• Jeppesen PB et al. (2001) — First human proof-of-concept in SBS — Gastroenterology

Regulatory & Prescribing Information

• FDA: Gattex (teduglutide) Prescribing Information
• FDA: Bulk Drug Substances Used in Compounding
• EMA: Revestive (teduglutide) — European Medicines Agency

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.